Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial - PubMed (original) (raw)
Clinical Trial
. 2018 Aug 20;36(24):2532-2537.
doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10.
Ronglai Shen 1, Darren Buonocore 1, Zachary T Olah 1, Ai Ni 1, Michelle S Ginsberg 1, Gary A Ulaner 1, Michael Offin 1, Daniel Feldman 1, Todd Hembrough 1, Fabiola Cecchi 1, Sarit Schwartz 1, Nick Pavlakis 1, Stephen Clarke 1, Helen H Won 1, Edyta B Brzostowski 1, Gregory J Riely 1, David B Solit 1, David M Hyman 1, Alexander Drilon 1, Charles M Rudin 1, Michael F Berger 1, Jose Baselga 1, Maurizio Scaltriti 1, Maria E Arcila 1, Mark G Kris 1
Affiliations
- PMID: 29989854
- PMCID: PMC6366814
- DOI: 10.1200/JCO.2018.77.9777
Clinical Trial
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T Li et al. J Clin Oncol. 2018.
Erratum in
- Errata.
[No authors listed] [No authors listed] J Clin Oncol. 2019 Feb 1;37(4):362. doi: 10.1200/JCO.18.02207. J Clin Oncol. 2019. PMID: 30695650 Free PMC article. No abstract available.
Abstract
Purpose Human epidermal growth factor receptor 2 ( HER2, ERBB2)-activating mutations occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in a cohort of patients with HER2-mutant lung cancers as part of a phase II basket trial. Patients and Methods Patients received ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression. The primary end point was overall response rate using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A Simon two-stage optimal design was used. Other end points included progression-free survival and toxicity. HER2 testing was performed on tumor tissue by next generation sequencing, fluorescence in situ hybridization, immunohistochemistry, and protein mass spectrometry. Results We treated 18 patients with advanced HER2-mutant lung adenocarcinomas. The median number of prior systemic therapies was two (range, zero to four prior therapies). The partial response rate was 44% (95% CI, 22% to 69%), meeting the primary end point. Responses were seen in patients with HER2 exon 20 insertions and point mutations in the kinase, transmembrane, and extracellular domains. Concurrent HER2 amplification was observed in two patients. HER2 immunohistochemistry ranged from 0 to 2+ and did not predict response, and responders had low HER2 protein expression measured by mass spectrometry. The median progression-free survival was 5 months (95% CI, 3 to 9 months). Toxicities included grade 1 or 2 infusion reactions, thrombocytopenia, and elevated hepatic transaminases. No patient stopped therapy as a result of toxicity or died on study. Conclusion Ado-trastuzumab emtansine is an active agent in patients with HER2-mutant lung cancers. This is the first positive trial in this molecular subset of lung cancers. Further use and study of this agent are warranted.
Trial registration: ClinicalTrials.gov NCT02675829.
Figures
Fig 1.
Waterfall plot of best response. RECIST, Response Evaluation Criteria in Solid Tumors.
Fig 2.
Swimmers plot of progression-free survival.
Fig A1.
Basket trial schema. CLIA, Clinical Laboratory Improvement Amendments; FISH, fluorescent in situ hybridization; IV, intravenous; NGS, next-generation sequencing; RECIST, Response Evaluation Criteria in Solid Tumors.
Fig A2.
Progression-free survival (PFS) of patients with _HER2_-mutant lung cancers (N = 18). The median PFS for all patients was 5 months (95% CI, 3 to 9 months), and median PFS for the responders was 6 months (95% CI, 4 months to not reached).
Similar articles
- Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review.
Wang H, He Y, Zhao W, Tong Z. Wang H, et al. Anticancer Drugs. 2022 Sep 1;33(8):773-777. doi: 10.1097/CAD.0000000000001369. Epub 2022 Aug 10. Anticancer Drugs. 2022. PMID: 35946510 Review. - A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K. Hotta K, et al. J Thorac Oncol. 2018 Feb;13(2):273-279. doi: 10.1016/j.jtho.2017.10.032. Epub 2017 Dec 5. J Thorac Oncol. 2018. PMID: 29313813 Clinical Trial. - A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
Kashiwaba M, Ito Y, Takao S, Doihara H, Rai Y, Kanatani K, Takashima S, Masuda N. Kashiwaba M, et al. Jpn J Clin Oncol. 2016 May;46(5):407-14. doi: 10.1093/jjco/hyw013. Epub 2016 Feb 24. Jpn J Clin Oncol. 2016. PMID: 26917603 Clinical Trial. - Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.
Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Jhaveri KL, et al. Ann Oncol. 2019 Nov 1;30(11):1821-1830. doi: 10.1093/annonc/mdz291. Ann Oncol. 2019. PMID: 31504139 Free PMC article. Clinical Trial. - Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA, Cicci TA, Auten JJ, Lowe DK. Corrigan PA, et al. Ann Pharmacother. 2014 Nov;48(11):1484-93. doi: 10.1177/1060028014545354. Epub 2014 Jul 31. Ann Pharmacother. 2014. PMID: 25082874 Review.
Cited by
- Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.
Hong L, Patel S, Drusbosky LM, Xiong Y, Chen R, Geng R, Heeke S, Nilsson M, Wu J, Heymach JV, Wang Y, Zhang J, Le X. Hong L, et al. NPJ Precis Oncol. 2024 Oct 1;8(1):217. doi: 10.1038/s41698-024-00720-9. NPJ Precis Oncol. 2024. PMID: 39354054 Free PMC article. - Management of Pulmonary Toxicities Associated with Systemic Therapy in Non Small Cell Lung Cancer.
Velimirovic M, Brignola M, Chheng E, Smith M, Hassan KA. Velimirovic M, et al. Curr Treat Options Oncol. 2024 Sep 20. doi: 10.1007/s11864-024-01257-6. Online ahead of print. Curr Treat Options Oncol. 2024. PMID: 39302574 Review. - A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.
Thavaneswaran S, Lin F, Grady JP, Espinoza D, Huang ML, Chinchen S, Sebastian L, Kansara M, Mersiades T, Lee CK, Desai J, Grimison P, Brown M, Millward M, Harrup R, O'Byrne K, Nagrial A, Craft P, Simes J, Joshua AM, Thomas DM. Thavaneswaran S, et al. NPJ Precis Oncol. 2024 Sep 9;8(1):195. doi: 10.1038/s41698-024-00698-4. NPJ Precis Oncol. 2024. PMID: 39251683 Free PMC article. - Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report.
Ali ST, VanderWeele DJ. Ali ST, et al. Curr Oncol. 2024 Jul 14;31(7):4015-4021. doi: 10.3390/curroncol31070298. Curr Oncol. 2024. PMID: 39057170 Free PMC article. - Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives.
Zhang H, Zhang Y, Zhu Y, Dong T, Liu Z. Zhang H, et al. Front Oncol. 2024 Jul 11;14:1387345. doi: 10.3389/fonc.2024.1387345. eCollection 2024. Front Oncol. 2024. PMID: 39055566 Free PMC article. Review.
References
- Stephens P, Hunter C, Bignell G, et al. : Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526, 2004 - PubMed
- Wang SE, Narasanna A, Perez-Torres M, et al. : HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38, 2006 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous